非霍奇金淋巴瘤282例临床分析

Clinical analysis of 282 patients with non-Hodgkin′s lymphoma

目的 :分析非霍奇金淋巴瘤 (NHL)的分型、分期及预后。方法 :对本院 2 82例非霍奇金淋巴瘤患者进行回顾性研究。结果 :B细胞性完全缓解率及五年生存率高于T细胞性 (P <0 .0 5 ) ,低度、中度、高度恶性非霍奇金淋巴瘤完全缓解率及五年生存率有显著差别 (P <0 .0 5 ) ,选择环磷酰胺、长春新碱、阿霉素、强的松 (CHOP)方案其完全缓解率及五年生存率高于环磷酰胺、长春新碱、足叶乙甙、强的松 (COP +VP1 6 )方案 (P <0 .0 5 )。结论 :合理分型、分期对非霍奇金淋巴瘤预后判断有重要临床意义。

Objective To analyze the classification, stage and prognosis of non Hodgkin′s lymphoma (NHL). Methods Two hundred eighty two patients with NHL were retrospectively reviewed. Results The complete remission (CR) rate and 5 year survival rate of B cell NHL were higher than those of T cell NHL( P <0.05). There were significant differences in CR rate and 5 year survival rate among the low grade, the intermediate grade and the high grade NHL( P <0.05). The CR rate and 5 year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP+VP16) ( P <0.05). Conclusion Rational classification and staging play an important role in the prognosis of NHL. CHOP based scheme may be regarded as the first choice and the standard scheme of treatment.